Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) - Pipeline Review, H1 2016

  • ID: 3775400
  • Report
  • 141 pages
  • Global Markets Direct
1 of 6

FEATURED COMPANIES

  • AbbVie Inc.
  • Biocon Limited
  • Johnson & Johnson
  • Mycenax Biotech Inc.
  • Oncobiologics, Inc.
  • Panacea Biotec Limited
  • MORE
Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) - Pipeline Review, H1 2016

Summary

‘Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) - Pipeline Review, H1 2016’, provides an overview of the Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease)
- The report reviews pipeline therapeutics for Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) therapeutics and enlists all their major and minor projects
- The report assesses Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • AbbVie Inc.
  • Biocon Limited
  • Johnson & Johnson
  • Mycenax Biotech Inc.
  • Oncobiologics, Inc.
  • Panacea Biotec Limited
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) Overview

Therapeutics Development

Pipeline Products for Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) - Overview

Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) - Therapeutics under Development by Companies

Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) - Products under Development by Companies

Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) - Companies Involved in Therapeutics Development

AbbVie Inc.

Alteogen Inc.

Biocon Limited

Coherus BioSciences, Inc.

Epirus Biopharmaceuticals, Inc.

Johnson & Johnson

Mabion SA

Marathon Pharmaceuticals, LLC

Momenta Pharmaceuticals, Inc.

Mycenax Biotech Inc.

Novartis AG

Oncobiologics, Inc.

Oncodesign SA

Panacea Biotec Limited

Pfizer Inc.

Sandoz International GmbH

Swedish Orphan Biovitrum AB

Therapeutic Proteins International, LLC

UCB S.A.

Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

abatacept - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

abatacept biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ABT-122 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

adalimumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

adalimumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

adalimumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

adalimumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

adalimumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

adalimumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

adalimumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

adalimumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

adalimumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

adalimumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

adalimumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

anakinra (recombinant) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

canakinumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

certolizumab pegol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

deflazacort - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

etanercept biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

etanercept biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

etanercept biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

etanercept biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

etanercept biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

etanercept biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

golimumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

methotrexate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit RIP2 for Polyarthritis, Gastrointestinal Disorders and Rheumatoid Arthritis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tocilizumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tocilizumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tocilizumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tofacitinib citrate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

upadacitinib tartrate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) - Dormant Projects

Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) - Discontinued Products

Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) - Product Development Milestones

Featured News & Press Releases

May 27, 2016: Simponi Receives CHMP Positive Opinion For Treatment Of Polyarticular Juvenile Idiopathic Arthritis

Apr 21, 2016: European patent granted on new formulation of Kineret (anakinra)

Mar 23, 2016: Sobi to initiate clinical development programs in acute gout and Still disease, and receives US patent on new formulation for Kineret (anakinra)

Aug 19, 2015: Kineret receives Australian regulatory approval for use in Systemic Juvenile Idiopathic Arthritis

Feb 12, 2015: ONS-3010 (Humira/Adalimumab Biosimilar) Meets Primary Endpoints In First Clinical Study

Sep 03, 2013: Novartis receives EU approval for Ilaris in active Systemic Juvenile Idiopathic Arthritis, a serious form of childhood arthritis

Jul 25, 2013: CHMP Adopts Positive Opinion For Novartis's Ilaris

May 10, 2013: Novartis's Ilaris Receives Approval From FDA For Treatment Of Active Systemic Juvenile Idiopathic Arthritis

Dec 19, 2012: Novartis's ACZ885 Significantly Relieves Symptoms In Patients With Serious Form Of Childhood Arthritis In Phase III Trials

Nov 08, 2012: Bristol-Myers Squibb To Present New Investigational Data On Orencia At 2012 American College Of Rheumatology Annual Scientific Meeting

Jun 06, 2012: Novartis Announces New Data From Two Trials Of ACZ885 At Annual Congress Of EULAR 2012

Nov 16, 2011: Novartis Study Shows ACZ885 Provides Substantial Symptom Relief In 84% Of Patients With Most Serious Form Of Childhood Arthritis

Nov 07, 2011: Novartis's Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use In 45% Of Patients With Serious Form Of Childhood Arthritis

Sep 16, 2011: Novartis Study Says ACZ885 Provided Substantial Symptom Relief In 84% Of Patients With Childhood Arthritis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease), H1 2016

Number of Products under Development by Companies, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Development, H1 2016

Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016 (Contd..1)

Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) - Pipeline by AbbVie Inc., H1 2016

Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) - Pipeline by Alteogen Inc., H1 2016

Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) - Pipeline by Biocon Limited, H1 2016

Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) - Pipeline by Coherus BioSciences, Inc., H1 2016

Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) - Pipeline by Epirus Biopharmaceuticals, Inc., H1 2016

Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) - Pipeline by Johnson & Johnson, H1 2016

Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) - Pipeline by Mabion SA, H1 2016

Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) - Pipeline by Marathon Pharmaceuticals, LLC, H1 2016

Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) - Pipeline by Momenta Pharmaceuticals, Inc., H1 2016

Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) - Pipeline by Mycenax Biotech Inc., H1 2016

Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) - Pipeline by Novartis AG, H1 2016

Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) - Pipeline by Oncobiologics, Inc., H1 2016

Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) - Pipeline by Oncodesign SA, H1 2016

Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) - Pipeline by Panacea Biotec Limited, H1 2016

Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) - Pipeline by Pfizer Inc., H1 2016

Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) - Pipeline by Sandoz International GmbH, H1 2016

Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) - Pipeline by Swedish Orphan Biovitrum AB, H1 2016

Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) - Pipeline by Therapeutic Proteins International, LLC, H1 2016

Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) - Pipeline by UCB S.A., H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Stage and Target, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) - Dormant Projects, H1 2016

Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) - Discontinued Products, H1 2016

List of Figures

Number of Products under Development for Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease), H1 2016

Number of Products under Development by Companies, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Top 10 Targets, H1 2016

Number of Products by Stage and Top 10 Targets, H1 2016

Number of Products by Top 10 Mechanism of Actions, H1 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Types, H1 2016
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • AbbVie Inc.
  • Biocon Limited
  • Johnson & Johnson
  • Mycenax Biotech Inc.
  • Oncobiologics, Inc.
  • Panacea Biotec Limited
  • MORE
Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) Still’s disease is one type of juvenile rheumatoid arthritis (JRA) and is also known as systemic-onset juvenile idiopathic arthritis. Still's disease is a disorder featuring inflammation. It is characterized by high spiking fevers, salmon-colored rash that comes and goes, and arthritis. Symptoms include poor appetite, nausea, and weight loss is common. Other symptoms include swelling of the lymph glands, enlargement of the spleen and liver, and sore throat. Treatment includes anti-inflammatory drugs, such as non-steroid drugs (NSAIDs) and steroids.

Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) pipeline therapeutics constitutes close to 32 molecules. which approximately 32 molecules are developed by Companies.The molecules developed by Companies in Pre-Registration, Phase III, Phase I, Preclinical and Discovery stages are 3, 8, 2, 16 and 3 respectively.

Our latest report Systemic-Onset Juvenile Idiopathic Arthritis – Pipeline Review, H1 2016, outlays comprehensive information on the therapeutics under development for Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews of key players involved in therapeutic development for Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) and features dormant and discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Product cover images may vary from those shown
5 of 6
AbbVie Inc.
Alteogen Inc.
Biocon Limited
Coherus BioSciences, Inc.
Epirus Biopharmaceuticals, Inc.
Johnson & Johnson
Mabion SA
Marathon Pharmaceuticals, LLC
Momenta Pharmaceuticals, Inc.
Mycenax Biotech Inc.
Novartis AG
Oncobiologics, Inc.
Oncodesign SA
Panacea Biotec Limited
Pfizer Inc.
Sandoz International GmbH
Swedish Orphan Biovitrum AB
Therapeutic Proteins International, LLC
UCB S.A.
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll